Evotec and IMP will apply disease models to identify targets that Boehringer will chose from and further validate.
Evotec, Boehringer Ingelheim, and the Research Institute of Molecular Pathology in Vienna (IMP) will jointly identify novel targets as potential points of intervention in the treatment of Alzheimer’s disease (AD).
Evotec scientists together with the IMP will apply validated disease models to identify novel AD targets. Based on these models, Boehringer Ingelheim will select and further validate target candidates for its in-house drug discovery program.
The contract includes an option for Evotec to support Boehringer Ingelheim (BI) in the target validation process. Evotec could then be eligible for milestone payments of up to Euro 20 million plus royalties.
